Torasemide and furosemide: similarities and differences


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The aim of the article is to evaluate the efficacy and safety of loop diuretics - torasemide and furosemide in patients with chronic heart failure and arterial hypertension. Torasemide has shown to have less inter-and intra-individual variation in bioavailability and a longer duration of action compared with furosemide. In the majority of clinical trials have been shown than torasemide exerts more favorable effect on signs of disease, functional status of patients and quality of life than furosemide. Torasemide treatment induced significant decreases in left ventricular systolic wall stress and the plasma level of aldosterone. Moreover, torasemide reduces total and cardiovascular death and readmission to the hospital. New mechanisms of action of torasemide are discussed.

Full Text

Restricted Access

About the authors

Viktor Vladimirovich Cheltsov

Russian peoples' friendship university

Email: vcheltsov@mail.ru
MD, professor of the Department of general and clinical pharmacology, Medical faculty

References

  1. Siscovic D.S., Raghunathan T.E., Psaty B.M. Diuretic therapy for hypertension and the risk of primary cardiac arrest. N. Engl. J. Med. 1994;330:1852-7.
  2. Reyes A.J., Taylor S.H. Diuretics in cardiovascular medicine: the new clinicopharmacological bases that matter. Cardiovasc. Drugs Ther. 1999;13:371-98.
  3. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН. Сердечная недостаточность.2013;7(81):379-472. [National recommendations on the diagnosis and treatment of chronic heart failure. Heart failure. 2013;7(81):379-472 (in Russian)]
  4. Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Association and Management of Heart Failure. Circulation, 1995;92:2764-84.
  5. Remme W.J., Swedberg K. Task force for the diagnosis and treatment of chronic heart failure, European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur. Heart J. 2001;22:1527-60.
  6. Murray M.D., Haag K.M., Black P.K., Hall S.D., Brater D.C. Variable furosemide absorption and poor predictability of response in elderly patients. Pharmacotherapy. 1997;17:98-106.
  7. Brater D.C. Diuretic therapy. N. Engl. J. Med. 1998;339:387-95.
  8. Vargo D.L., Kramer W.G., Back P.K., Smith W.B., Serpas T., Brater D.C. Bioavailability, pharmacokinetics and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin. Pharm. Ther.1995;57:601-9.
  9. Cosin J., Diez J., on behalf of the TORIC investigators. Torasemide in chronic heart failure: results of the TORIC study. Eur. J. Heart Failure. 2002;4:507-13.
  10. Muller K., Gamba G., Jaquet F., Hess B. Torasemide vs furosemide in primary care patients with chronic heart failure NYHA II to IV - efficacy and quality of life. Eur. J. Heart Failure. 2003;5:793-801.
  11. Yamato M., Sasaki T., Honda K., Fukuda M., Akutagawa O., Okamoto M., Hayashi T. Effects of torasemide on left ventricular function and neurohumoral factors in patients with chronic heart failure. Circ. J. 2003;67:384-390.
  12. Rihal C.S., Nishimura R.A., Hatle L.K., Bailey K.R., Tajik A.J. Systolic and diastolic dysfunction in patients with clinical diagnosis of dilated cardiomyopathy: relation to symptoms and prognosis. Circulation, 1994;90:2772-9.
  13. Xie G.Y., Berk M.R., Smith M.D., Gurley J.C., DeMaria A.N. Prognostic value of Doppler transmitral flow patterns in patients with congestive heart failure. J. Am. Coll. Cardiol. 1994;24:132-9.
  14. Nishimura R.A., Tajik A.J. Evaluation of diastolic filling of left ventricle in health and disease: Doppler echocardiography is the clinician's Rosetta stone. J. Am. Coll. Cardiol. 1997;30:8-18.
  15. Yamamoto К., Burnett J.C., Jougasaki M., Nishimura R.A., Bailey K.R., Saito Y., Nakao K., Redfiel M.M. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension. 1996;28:988-94.
  16. Weber K.T., Brilla C. Pathological hypertrophy and cardiac interstitium: Fibrosis and renin-angiotensin-aldosterone system. Circulation. 1991:83;1849-65.
  17. Young M., Fullerton M., DiHey R., Funder J.W. Mineralocorticoids, hypertension and cardiac fibrosis. J. Clin. Invest. 1994;92:2578-83.
  18. Pitt B., Zannad F., Remme W.J., Cody R., Castaigne A., Perez A., Palensky J., Wittes J., for the randomized aldactone evaluation study investigators. N. Engl. J. Med. 1999:341:709-17.
  19. Goodfriend T.L., Ball D.L., Oelkers W., Bahr V. Torasemide inhibits aldosterone secretion in vitro. Life Sci. 1998;63:PL45-PL50.
  20. Uchida T., Yamanaga K., Nishikawa M., Kido H., Watanabe M. Anti-aldosteronergic effect of torasemide. Eur.J.Pharmacol. 1991;205:145-50.
  21. Uchida T., Yamanaga K., Kido H., Ohtaki Y., Watanabe M. Diuretic and vasodilating actions of torasemide. Cardiology. 1994;84(Suppl. 2):14-7.
  22. Tsutamoto T., Wada A., Maeda K., Mabuchi N., Hayashi M., Tsutsui T., Ohnishi M., Sawaki M., Fujii M., Matsumoto T., Matsui T., Kinoshita M. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J. Am. Coll. Cardiol. 2001;37:1228-33.
  23. Goebel K.M. Six-week study of torasemide in patients with congestive heart failure. Clin. Ther. 1993;15:1051-9.
  24. Brower G.L., Gardner J.D., Forman M.F., Murray D.B., Voloshenyuk T., Levick S.P., Janicki J.S. The relationship between myocardial extracellular matrix remodeling and ventricular function. Eur. J. Cardiothoracic surgery. 2006;30:604-10.
  25. Burlew B.S., Weber K.T. Connective tissue and the heart. Functional significance and regulatory mechanisms. Cardiol. Clin. 2000;18:435-42.
  26. Weber K.T., Eghbali M. Collagen matrix synthesis and degradation in the development and regression of left ventricular hypertrophy. Cardiovasc. Rev. Rep. 1991;12:61-9.
  27. Querejeta R., Lopes B., Gonzales A., Sanchez E., Larman M., Diez J. Increased collagen type 1 synthesis in patients with heart failure of hypertensive origin. Relation to myocardial fibrosis. Circulation. 2004;1 10:1263-8.
  28. Lopez B., Querejeta R., Gonzalez A., Sanchez E., Larman M., Diez J. Effects of loop diuretics on myocardial fibrosis on chronic heart failure. J. Am. Coll. Cardiol. 2004;43:2028-35.
  29. Lopez B., Gonzalez A., Beaumont J., Querejeta R., Larman M., Diez J. Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. J. Am. Coll. Cardiol. 2007;50: 859-67.
  30. Liguori A., Casini A., Di Loreto M., Andreini I., Napoli C. Loop diuretics enhance the secretion of prostacyclin in vitro, in health persons and in patients with chronic heart failure. Eur. J. Clin. Pharmacol. 1999;55:117-24.
  31. Yu H., Gallagher A.M., Garfin P.M., Printz M.P. Prostacyclin release by rat cardiac fibroblasts: inhibition of collagen expression. Hypertension, 1997;30:1047-53.
  32. Kasama S., Toyama T., Hatori T., Sumino H., Kumakura H., Takayama Y., Ichikawa S., Suzuki T., Kurabayashi M. Effects of torasemide on cardiac sympathetic nerve activity and left ventricular remodelling in patients with congestive heart failure. Heart. 2006;92:1434-40.
  33. Muniz P., Fortuno A., Zalba G., Fortuno M.A., Diez J. Effects of loop diuretics on angiotensin II-stimulated vascular smooth muscle cell growth. Nephrol. Dial. Transplant. 2001;16 (Suppl. 1):14-7.
  34. Lopez B., Querejeta R., Gonzalez A., Beaumont J., Larman M., Diez J. Impact of treatment on myocardial lysyl oxidase expression and collagen cross-linking in patients with heart failure. Hypertension. 2009;53:236-42.
  35. Stroupe K.T., Forthofer M.M., Brater D.C., Murray M.D. Healthcare costs of patients with heart failure with torasemide or furosemide. Pharmacoeconomics. 2000;17(5):429-40.
  36. Young M., Plosker G.L. Torasemide: a pharmacoeconomic review of its use in chronic heart failure. Pharmacoeconomics. 2001;19(6):679-703.
  37. Diez J., Frohlich E.D. A translation approach to hypertensive heart disease. Hypertension. 2010;55:1-8.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies